EP1318826A2 - Use of buchu extracts for hypertension - Google Patents

Use of buchu extracts for hypertension

Info

Publication number
EP1318826A2
EP1318826A2 EP01977948A EP01977948A EP1318826A2 EP 1318826 A2 EP1318826 A2 EP 1318826A2 EP 01977948 A EP01977948 A EP 01977948A EP 01977948 A EP01977948 A EP 01977948A EP 1318826 A2 EP1318826 A2 EP 1318826A2
Authority
EP
European Patent Office
Prior art keywords
buchu
fractions
oil
inflammatory
vitamin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01977948A
Other languages
German (de)
French (fr)
Inventor
Michael D. Stander
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP1318826A2 publication Critical patent/EP1318826A2/en
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/75Rutaceae (Rue family)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/02Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Definitions

  • Integrins There are 2 that are present on the cell surfaces of neutrophils and both are expressed constitutionally but up regulated (expressed more) upon activation: the so- called LFA-1 (CDl la CD18 heterodimer) and the Mac-1 (CDllb/CD18 hetero imer). Both of these surface molecules can be measured and quantified by means of flow cytometry (a specialized technique that measures the amount of binding which takes place between the antibody specific for these molecules and the cell in question).
  • Figure 1 Expression of MAC-1 (CDllb/CD18) by Neutrophi ⁇ es and monocytes post activation in the presence/absence of Buchu oil distillate at different dilutions:

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Botany (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Saccharide Compounds (AREA)

Abstract

A method is described for obtaining a composition for the treatment of inflammatory and/or hypertensive conditions. The plant (Barosma betuliona, agosthoma betuliona or agosthoma crenulata) is vacuum steam distilled and fractions rich in one or more of diphenol, diosmin, quercetin and rutin are separated and used in dilutions of from 1:400 to 1:3200.

Description

USE OF BUCHU EXTRACTS FOR HYPERTENSION TECHNICAL FIELD OF THE INVENTION
This invention relates to a composition of matter which is useful in the treatment of hypertension and inflammatory conditions
BACKGROUND ART
Inflammation and hypertension are two well known conditions and it is not considered necessary to explain, in a patent specification, the medical reactions responsible for the hypertensive and inflammatory conditions.
It is known that oil of buchu (Barosma betuliona or agosthoma betulina or agosthoma crenulata) has been used as an anti -inflammatory agent, usually in the form of a tea prepared from the leaves of the plant.
As a result of extensive experimentation, it has surprisingly been found that certain fractions of the distillate of the buchu oil have unexpectedly beneficial properties.
DISCLOSURE OF THE INVENTION
According to the invention a composition for the treatment of inflammatory and/or hypertensive conditions includes one or more fractions of the vacuum steam distillation of buchu oil, whether as the raw product obtained directly from the plant or as a residue from a process aimed at the separation of fractions for other purposes , the fraction/s comprising those rich in one or more of diphenol, diosmin, quercetin and rutin. Hesperidin and Vitamin B and E may also be present in substantial quantities.
Such fractions are determined by experimentation and it has surprisingly been shown that such fractions exhibit an action far in excess of other fractions. As an anti-inflammatory agent, the fraction/s exhibit unexpected action on neutrophil and monocyte functions; whereas as an anti-hypertensive agent the administration leads to unexpectedly good normalisation of blood pressure without any need for additional medication. This may be due to the increased secretion of renin by the kidneys.
The invention also extends to a method of manufacturing a composition useful in the treatment of inflammatory and/or anti-hypertensive conditions, comprising the steps of selecting one or more fractions of the vacuum stream distillation of buchu oil, the fractions being rich in diphenol, diosmin, quercetin and rutin.
A. ANTI-INFLAMMATORY ACTION
EXPERIMENTAL PROCEDURES:
♦ Neutrophil Functions:
e) Adhesion molecule.;
Upon activation by complement peptides, the neutrophils up-rcgulatc the expression of the adhesion molecules on their surfaces in order to adhere more efficiently to the celJ wall of the bacteria and endothelial cells. These adhesion molecules are called the β-
Integrins. There are 2 that are present on the cell surfaces of neutrophils and both are expressed constitutionally but up regulated (expressed more) upon activation: the so- called LFA-1 (CDl la CD18 heterodimer) and the Mac-1 (CDllb/CD18 hetero imer). Both of these surface molecules can be measured and quantified by means of flow cytometry (a specialized technique that measures the amount of binding which takes place between the antibody specific for these molecules and the cell in question).
Heparinised blood from healthy volunteers was obtained in vacuutainer tubes. The donating volunteers were not on any anti-hiflammatory medication. An aliquot of whole blood was pre-incubated (20 minutes at room temperature) with various dilutions of the 25 Buchu essential oil distillate prior to being stimulated using PMA (phorbol myristate acetate, an activator used in vitro). The experimental outline was as follows:
I. Blood incubated with medium
II. Blood with stimulant (PMA)
III. Blood with stimulant (PMA) AND Buchu oil dilution in a increasing doses Measurement of Mae- 1 was conducted using antibodies that bind to these structures and analysed by flow cytometry. Briefly, the blood aliquot prc-incubatcd and activated with the activator was treated with a solution to lyse the red blood cells, The non-lysed cells were washed with an isoionic solution and analysed on a flow cytometry. Fifteen thousand events were accumulated and the % positive events as well as the degree υf positivtty (mean channel fluorescent: MCF) was measured.
e) Respiratory burst:
When the neutrophils arrive at the site of infection, they eat the organisms invading the host and once inside the cytoplasm of the cells, activate a series of enzymes on the inside of the membrane to generate toxic oxygen radicals. This is referred to as the oxygen- dependent killing mechanism. This respiratory burst can be measured by using fluorochrom.es which change colour when in the presence of the oxygen radicals generated. This change can be quantified by flow cytometry,
A commercial kit (BurstTest) was used to measure the ability of neutrophils to mount a respiratory burst. For this, blood was obtained from healthy volunteers as above. The aliquots were pre-incubated with dilutions of the Buchu oils prior to being activated with whole bacteria (included in the commercial kit) and processed further. The experimental outline was as follows:
I. Blood with medium II. Blood with activator (E coli)
III. Blood with activator (as above) AND Buchu oil in increasing doses
Following the pre-iπcubation and activation, the red blood cells were lysed and ihe non- lysed cells washed and analysed on a flow cytometry. The % positive cells as well as the MCF measured. Fifteen thousand events were accumulated for the analysis.
♦ Moπocyte Functions:
a) Expression of adhesion molecules:
Similarly to the measurement of adhesion molecules on neutrophils, antibodies binding to the Mac-1 will be used to measiu'e the expression of these molecules when moπocytes are activated in the presence/absence of Buchu oil extract (see above). The same reagents are used for this procedure. b) Release of pro-inflammatory mυπokincs by moπocytes:
When activated, monocytes release IL6 and TNF-α that are responsible for the recruitment of other immune cells and initiate a self-perpetuating chronic inflammatory process. These factors can be quantified by activating monocytes with bacterial products (endotoxin) and measuring the soluble factors by immunological assays (KL1SA) using specific antibodies. The aims of these experiments were to measure the release of 1L6 in the following way. Whole blood was collected into vacuutainer tubes and the mononuclcar cells isolated by density centrifugaiion. The monocyte rich fraction was obatincd by adherence to the wells of a multi-well culture plate. The adherent cells were stimulated to release the monokine IL6 by being activated by a pre-detcrmincd concentration of bacterial endotoxin (Lipopolysaccharide). The experimental outline was. as follows:
I. Cells with medium
II. Cells with endotoxin III. Cells with endotoxin with Buchu oil in increasing doses
The cells were incubated for 17 hours at 37°C and 5% CG2. The following day, the supernatant was collected and assayed for their contents in IL6 by an in-house ELISA method using external standards as calibrators. The absolute concentrations of IL<5 in the respective supernatants were calculated from a standard curve derived from the standards, The results were expressed as Units of IL6 (pg/ml) released by the respective culture wells.
RESULTS:
c) Expression of Adhesion molecules (MAC-1) on Neutrophils and Moπocytes:
As shown in Figure 1, the neutrophils pre-incubated with the various dilutions of Buchu oil distillate showed a statistically significant decrease in their ability to express the MAC-1 adhesion molecules as measured by flow cytometry. indeed, when the cells arc activated by PMA, they increase their expression of MAC-1 (compare negative control versus positive control). When the cells are activated in the presence of increasing dilutions of the Buchu oil, the expression is significantly inhibited (p < 0.05) by diltions of 1 :400; 1 :800 and 1 : 1600. Thereafler, the inhibitory effects are diluted out. TMs effect was not paralleled by the monocytes under identical conditions of culture.
Figure 1: Expression of MAC-1 (CDllb/CD18) by Neutrophiϊes and monocytes post activation in the presence/absence of Buchu oil distillate at different dilutions:
JO Neutrophils i n Monocytes
Negative Positive 1 in 400 1 in 800 1 in 1600 1 in 3200 Control Con trol
Oil Dilution
P < 0.05
e) Effects of different Buchu oil distillates on the expression MAC-1 in vitro:
Although most of the oil distillates tested yielded inhibition of the MΛC-1 expression by neutrophils, it was evident when each oil was tested separately that same of the oils had higher activity when analysed separately. As indicated in Figure 2, some oils weie more potent inhibitors of the expression of MAC-1 upon stimulation by PMA. The same experimental procedure was followed as above. It can be seen from Figuie 2 that certain preparations of the distillate ate more effective in the inhibition of MAC- 1 expression: B16 and B25A show higher inhibition than the other 3 batches of oils tested.
Figure 2: The effects of different oil distillates at the same dilution (1 :400) on the expression of MAC-1 (CDllb/CDlS) on neutrophils and moπocytes post-actϊvalion by PMA:
ΘNeutrophifs 1 ι H Monocytes
Negative Positive B14 B1 S B16 B25A B26B Control Control
Oil Lot P < 0.05 e) The effects of Buchu oil distillates on the Respiratory burst of neutrophils:
During the initial pahsc of neutrophil functions, the internalised organism or particle is destroyed by an oxygen-dependent process which ultimately leads to the generation of oxygen radicals (O2 ~). These radicals arc protective when tliis is generated in Ihe cytoplasm of the cell in that it kills the bacterium. However, when these are released to the external medium, it can damage healthy tissues in the vicinity of the phagocytic cell
The ability of Buchu oils to influence the generation of oxygen radicals was measured by flow cytometry. As shown in Figure 3, it is evident that at the different dilutions of the oils, the oxidative burst (respiratory burst) of neutrophils was significantly inhibited by the oil distillate dilutions (from 1 :400 tol : 3200 dilution). Figure 3: Inhibition of Respiratory Burst of neutrophils by different Buchu oil dilutions,
P < U.05
Negative Positive 1 in 400 1 in 800 1 in 1600 1 in 3200 Control Control
Oil Dilution
e) Effects of various Buchu oil distillates on the Respirator)' Burst of Neutrophils:
It was evident during the measurement of tliis cellular function that certain batches were more potent in their inhibitory ability. This is shown in Figure 4 where various oil distillates were compared at the same dilution (1:400). It is obvious that batch B16, B25A and B25B were the most effective in this aspect although all had inhibitory activities (p < 0,05) | H Neutrophils [ 8a Monocytes _)
Oil Lot
Figure 4: Effects of different Buchu oil distillates on the Respiratory Burst of Neutrophils: all oils were tested at the same dilution (1:400).
e) The effects of Buchu oil distillate on the release of IL6 by activated monocytes:
During the chronic phases of inflammation, the cellular infiltrate made up primarily of monocytes and other monouclear cells release 1L6, a factor with varied biological activities including fever, pain, calcium mobilization from bone, etc This factor perpetuates the on-going inflammation and thus is pivotal in the tissue damage seen in these chronic conditions
Blood monocytes were pre-incubated with various dilutions of Buchu oil prior to being activated by endotoxin in order to induce the synthesis and release of ΪL6. As shown in Figure 5, it is evident that various dilutions of the Buchu oils were able to significantly inhibit the release of IL6 from monocytes.
_g_
Figure 5: Inhibition of ΪL6 release from monocytes in the presence of
Buchu oil distillate:
Oil Diiution P < 0.05
At both stimulus concentration (LPS 1 :100 and LPS 1:10), the 1:400 dilution was the most active in its inhibition. Once the oil was diluted out, this activity was lost.
DISCUSSION:
It has been shown by the present report that various Buchu oil distillates arc able to inhibit various processes involved during inflammation. The acute phase of the inflammatory process as measured by the expression of adhesion molecules such as MAC-1 (CD l ib/CD 18) on both monocytes and neutrophils as well as the respiratory burst of neutrophils were significantly inhibited by low dilutions of the oils tested. This inhibition was dose dependent since titering out of the oil lead to tliis effect being lost. Some oils were more effective in this process. One can mimic the chronic phase of inflammation by inducing and measuring the release of IL6 from activated monocytes. This was measured in the presence of Buchu oil and shown to be significantly inhibited at low dilutions of the oils.
B. ANTI-HYPERTENSIVE ACTION Experimental Cases: Case 1 :
A 70 year old woman (RH) who for 2 years suffered from high blood pressure. She started drinking 250 ml of Buchu water (an oil extract of the Buchu plant mixed into spring, water) each day and within a week, her blood pressure dropped from 150/90 to a more acceptable 140/80 (normal considering the age of this patient).
Case 2:
Mrs GK: suffered from high blood pressure for several years (4 years) necessitating medication which could not control this chronic condition. Several changes of her medication still did not manage to control her blood pressure which stood at 220/120. Four years later, she was introduced to the Buchu water. Within 2 months of using this product regularly, her hypertension has been controlled at 145/80 without any other medication for this serious condition.
Case 3: Mrs DG
This patient was diagnosed with a blood pressure of 160/95 and at other times 170/100. She was prescribed various medications that caused side effects and she was advised to stop the medication. She discovered the Buchu water product and since using the product, her condition improved: her blood pressure now stands at 130/75. She has since never shown signs of her previously chronic high blood pressure.

Claims

1. A method of preparing a composition for the treatment of inflammatory and/or hypertensive conditions characterised in that buchu oil or a product containing buchu oil is vacuum steam distilled, those fractions which are rich in one or more of diphenol, diosmin, quercetin and rutin being separated and incoiporated into a pharmaceutically acceptable form.
2. The method according to claim 1 characterised in that the fractions separated also contain one or more of hesperidin, Vitamin B and vitamin E.
3. The method according to either claim 1 or claim 2 characterised in that the fractions are diluted by a factor of between 1 :400 to 1 :3200.
4. A pharmaceutical composition for the treatment of inflammatory and/or hypertensive conditions characterised by including one or more fractions of the vacuum steam distillation of buchu oil, whether as the raw product obtained directly from the plant or as a residue from a process aimed at the separation of fractions for other purposes, the fraction s comprising those rich in one or more of diphenol, diosmin, quercetin and rutin.
5. The composition according to claim 4 characterised in that the fraction s also contain one or more of hesperidin, Vitamin B, and vitamin E.
6. A method of treating a subject suffering from inflammatory and/or hypertensive conditions characterised in the administration of a pharmaceutically sufficient amount of a composition according to claim 4 or claim 5.
EP01977948A 2000-09-11 2001-09-07 Use of buchu extracts for hypertension Withdrawn EP1318826A2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ZA200004785 2000-09-11
ZA200004785 2000-09-11
PCT/ZA2001/000136 WO2002020030A2 (en) 2000-09-11 2001-09-07 Use of buchu extracts for hypertension

Publications (1)

Publication Number Publication Date
EP1318826A2 true EP1318826A2 (en) 2003-06-18

Family

ID=25588902

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01977948A Withdrawn EP1318826A2 (en) 2000-09-11 2001-09-07 Use of buchu extracts for hypertension

Country Status (4)

Country Link
EP (1) EP1318826A2 (en)
AU (2) AU2001297027B2 (en)
CA (1) CA2425912A1 (en)
WO (1) WO2002020030A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0317985D0 (en) 2003-07-31 2003-09-03 Unilever Plc Plant and plant extracts and their use
MD3987C2 (en) * 2009-09-03 2010-07-31 Георге АНГЕЛИЧ Use of Diosmine for the treatment of advancing hepatic cirrhosis associated with cardiac insufficiency
MD3986C2 (en) * 2009-09-23 2010-07-31 Георге АНГЕЛИЧ Use of Diosmine for the treatment of portal gastropathies in the hepatic cirrhosis
IT1399465B1 (en) * 2010-04-22 2013-04-19 Bioway Di Patrucco Claudio HERBORISTIC AND FOOD PREPARATION FOR PROTECTIVE AND TONING ACTION OF ORGANS OF THE GENITO-URINARY SYSTEM BOTH FEMALE AND MALE, AND HAVING AN ADDITIONAL EFFECT FOR CHILDREN'S RE-BALANCING
MD4231C1 (en) * 2012-11-08 2014-01-31 Георге АНГЕЛИЧ Medicament based on troxerutin and carbazochrome for the treatment of portal gastropathies in hepatic cirrhosis
MD4232C1 (en) * 2012-11-08 2014-01-31 Георге АНГЕЛИЧ Medicament based on troxerutin and carbazochrome for the treatment of progressive hepatic cirrhosis associated with heart failure
US20170326193A1 (en) * 2014-12-01 2017-11-16 Cape Kingdom Nutraceuticals (Pty) Ltd Buchu preparations
EP3226881A4 (en) 2014-12-01 2018-09-05 Cape Kingdom Nutraceuticals (Pty) Ltd. Anti-viral therapeutic compositions
WO2016088029A1 (en) * 2014-12-01 2016-06-09 Cape Kingdom Nutraceuticals (Pty) Ltd Therapeutic compositions
WO2020053751A1 (en) * 2018-09-10 2020-03-19 Cape Kingdom Nutraceuticals Pty Ltd Anti-obesity therapeutic composition
WO2020053750A1 (en) * 2018-09-10 2020-03-19 Cape Kingdom Nutraceuticals Pty Ltd Pre-diabetic therapeutic composition

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0220030A2 *

Also Published As

Publication number Publication date
AU9702701A (en) 2002-03-22
WO2002020030A2 (en) 2002-03-14
WO2002020030A3 (en) 2002-12-27
CA2425912A1 (en) 2002-03-14
AU2001297027B2 (en) 2005-08-18

Similar Documents

Publication Publication Date Title
US6379714B1 (en) Pharmaceutical grade botanical drugs
Garcia-Velasco et al. Elevated soluble Fas ligand levels may suggest a role for apoptosis in women with endometriosis
RU2687498C2 (en) Algae extract for use as immunomodulatory agent
AU2001297027B2 (en) Use of buchu extracts for hypertension
JPH06172183A (en) Medicinal composition
Sela et al. Allicin inhibits SDF‐1α‐induced T cell interactions with fibronectin and endothelial cells by down‐regulating cytoskeleton rearrangement, Pyk‐2 phosphorylation and VLA‐4 expression
JP2009132739A (en) Use of at least one of cosmetically acceptable saponin or sapogenol as cosmetic agent for increasing amount of collagen iv in the dermal-epidermal junction
Hersey et al. Tumour‐related changes in natural killer cell activity in melanoma patients. Influence of stage of disease, tumour thickness and age of patients
AU2001297027A1 (en) Use of buchu extracts for hypertension
Roszman et al. Inhibition of lymphocyte responsiveness by a glial tumor cell-derived suppressive factor
Lee et al. Suppression of the onset and progression of collagen‐induced arthritis by chebulagic acid screened from a natural product library
Benencia et al. In vivo and in vitro immunomodulatory activities of Trichilia glabra aqueous leaf extracts
KR20000053988A (en) Pharmacolocial effect and extracting method for osteoporosis and rhematoid arthritis treatment by constituent drugs of oriental medicine
JP2004307458A (en) Galenical composition having anticancer/immune/hematopoietic function enhancing effect and oxidative living body damage suppressing effect and manufacturing method thereof
Stein et al. Non-lectin component in a fermented extract from Viscum album L. grown on pines induces proliferation of lymphocytes from healthy and allergic individuals in vitro
Oh et al. Histamine synthesis by non-mast cells through mitogen-dependent induction of histidine decarboxylase.
JP2001508448A (en) Complexes and combinations of fetuin and therapeutic agents
EP0607296A1 (en) Use of misoprostol for the treatment of late-phase allergy
US20080262080A1 (en) Allergy Suppressive Agent
KR100506396B1 (en) The pharmaceutical composition and its preparation method of herb mixture for cancer inhibition, recovery of immune system and protection of body from oxidative damage
US20120003178A1 (en) Evaluating the therapeutic potential of a glucan
KR100394147B1 (en) Pharmacolocial effect and extracting method for chronic osteoporosis and rhematoid arthritis treatment by constituent drugs of oriental medicine
Miyake et al. Oral administration of highly oligomeric procyanidins of Jatoba reduces the severity of collagen-induced arthritis
WO2019055513A1 (en) Inhibited expression of pd-l1 and enhanced expression of pd-1
Bonavida et al. Multistage model of natural killer cell-mediated cytotoxicity involving NKCF as soluble cytotoxic mediators

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030411

AK Designated contracting states

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

17Q First examination report despatched

Effective date: 20031001

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20051004